Alligator Bioscience

Declaration of Voting Results & Voting Rights Announcements • Dec 30, 2021

Change in number of shares and votes in Alligator Bioscience AB

During December 2021, the number of shares and votes in Alligator Bioscience AB ("Alligator") has increased as a result of the completion of the rights issue of shares which was resolved by the Board of Directors on 7 October 2021 and approved by the Extraordinary General Meeting held on 8 November 2021, as well as the directed issue of shares to guarantors in the rights issue which was resolved by the Board of Directors on 2 December 2021. Per 30 December 2021, the number of registered shares and votes in Alligator amounts to 220,584,878.

For more information, please contact:

Julie Silber, Investor Relations Phone: +46 46-540 82 23 E-mail: jur@alligatorbioscience.com

This information is such information as Alligator Bioscience AB is obliged to make public pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact person set out above, at 10:30 CET on 30 December 2021.

About Alligator Bioscience AB

Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator's pipeline includes the two key assets mitazalimab, a CD40 agonist, and ATOR-1017, a 4-1BB agonist. Furthermore, Alligator is codeveloping ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its proprietary technology platform, Neo-X-Prime™, with MacroGenics Inc. and novel drug candidates based on the RUBY™ bispecific platform with Orion Corporation. Out licensed programs include AC101, in phase II development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc. Alligator Bioscience's shares are listed on Nasdaq Stockholm (ATORX) and is headquartered in Lund, Sweden. For more information, please visit http://www.alligatorbioscience.com.